Brief: Algernon Receives U.S. FDA Clearance For Multinational Phase 2B/3 Human Study To Evaluate Ifenprodil As A Potential Therapeutic For Covid-19
04/06/2020 17:29
June 4 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON RECEIVES U.S. FDA CLEARANCE FOR MULTINATIONAL
PHASE
2B/3 HUMAN STUDY TO EVALUATE IFENPRODIL AS A POTENTIAL
THERAPEUTIC FOR COVID-19
Source text for Eikon: urn:newsml:reuters.com:*:nGNXbgvPm5
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement